The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting-Reference-Cited by-同舟云学术

The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting

Published:2017-03-14 Issue:3 Volume:10 Page:143-146
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clinical And Translational Science

Author:

Cavallari LH¹,Beitelshees AL²,Blake KV³,Dressler LG⁴,Duarte JD¹,Elsey A¹,Eichmeyer JN⁵,Empey PE⁶,Franciosi JP⁷,Hicks JK⁸,Holmes AM⁹,Jeng LJB¹⁰,Lee CR¹¹,Lima JJ³,Limdi NA¹²,Modlin J⁵,Obeng AO¹³,Petry N¹⁴,Pratt VM.¹⁵,Skaar TC¹⁶,Tuteja S¹⁷,Voora D¹⁸,Wagner M⁵,Weitzel KW¹,Wilke RA¹⁹,Peterson JF²⁰,Johnson JA¹

Affiliation:

1. Department of Pharmacotherapy and Translational Research; University of Florida; Gainesville Florida USA

2. Department of Medicine; University of Maryland; Baltimore Maryland USA

3. Biomedical Research Department; Nemours Children's Specialty Care; Jacksonville Florida USA

4. Personalized Medicine and Pharmacogenetics Program; Mission Health; Asheville North Carolina USA

5. Department of Oncology; St. Luke's Mountain States Tumor Institute; Boise Idaho USA

6. Department of Pharmacy and Therapeutics; Center for Clinical Pharmaceutical Sciences; University of Pittsburgh School of Pharmacy; Pittsburgh Pennsylvania USA

7. Biomedical Research Department; Nemours Children's Specialty Care; Orlando Florida USA

8. Division of Population Science; DeBartolo Family Personalized Medicine Institute; Moffitt Cancer Center; Tampa Florida USA

9. Department of Health Policy and Management; Richard M. Fairbanks School of Public Health; Indiana University - Purdue University; Indianapolis Indiana USA

10. Departments of Medicine, Pathology, and Pediatrics; University of Maryland School of Medicine; Baltimore Maryland USA

11. Division of Pharmacotherapy and Experimental Therapeutics; Eshelman School of Pharmacy; University of North Carolina at Chapel Hill; Chapel Hill North Carolina USA

12. Department of Neurology; University of Alabama; Birmingham Alabama USA

13. Charles Bronfman Institute for Personalized Medicine; Icahn School of Medicine at Mount Sinai; New York New York USA

14. Department of Pharmacy Practice; North Dakota State University; Fargo North Dakota USA

15. Department of Medical and Molecular Genetics; Indiana University School of Medicine; Indianapolis Indiana USA

16. Department of Medicine, Division of Clinical Pharmacology; Indiana University School of Medicine; Indianapolis Indiana USA

17. Division of Translational Medicine and Human Genetics; Perelman School of Medicine at the University of Pennsylvania; Philadelphia Pennsylvania USA

18. Center for Applied Genomics & Precision Medicine, Department of Medicine; Duke University; Durham North Carolina USA

19. Department of Internal Medicine; University of South Dakota; Sioux Falls South Dakota USA

20. Departments of Biomedical Informatics and Medicine; Vanderbilt University Medical Center; Nashville Tennessee USA

Funder

National Institutes of Health

University of Florida

University of Maryland Medical Center and University of Maryland School of Medicine Program for Personalized and Genomic Medicine

Office of the Vice Chancellor for Research, University of Illinois at Chicago

American Society of Health System Pharmacists

Penn Center for Precision Medicine at the Perelman School of Medicine at the University of Pennsylvania

University of Alabama

Birmingham Health Service Foundations' General Endowment Fund

Indiana University Health

Indiana University School of Medicine Strategic Research Initiative

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/cts.12456/fullpdf

Reference6 articles.

1. CPIC: Clinical pharmacogenetics implementation consortium of the pharmacogenomics research network;Relling;Clin. Pharmacol. Ther.,2011

2. A new initiative on precision medicine;Collins;N. Engl. J. Med.,2015

3. The IGNITE network: a model for genomic medicine implementation and research;Weitzel;BMC. Med. Genomics.,2016

4. Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update;Scott;Clin. Pharmacol. Ther.,2013

5. Prospective clinical implementation of CYP2C19-genotype guided antiplatelet therapy after PCI: a multi-site investigation of MACE outcomes in a real-world setting;Cavallari;Circulation.,2016

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular Pharmacogenetics: From Discovery of Genetic Association to Clinical Adoption of Derived Test;Pharmacological Reviews;2024-08-09

2. Towards consensus recommendations for pharmacogenetics testing;American Journal of Health-System Pharmacy;2024-06-24

3. CYP2C19 Genotype Is Associated With Adverse Cardiovascular Outcomes in Black Patients Treated With Clopidogrel Undergoing Percutaneous Coronary Intervention;Journal of the American Heart Association;2024-06-18

4. Early evaluation of a novel alert within cardiac procedural areas to facilitate genotype‐guided antiplatelet therapy;JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY;2024-05-03

5. A New Cloud-Native Tool for Pharmacogenetic Analysis;Genes;2024-03-11